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Abstract 
The aim of this article is to present the development of the pharmaceutical industry in Syria using national and international 
public data sources. At the end of the 80ies, the pharmaceutical industry in Syria was very poor, covering 6% of the national needs. 
In less than 20 years, with the government support in terms of legal frame and strategic political engagement, the Syrian 
pharmaceutical industry finally covered almost 90% of the national needs, in terms of drugs, and exported drugs in around 52 
Arabian countries. Beyond covering the local market, the main added values of this huge development consisted in exporting drugs 
in amount of 150 million dollars per year and providing jobs for 17000 Syrian people, out of which around 85% are women. Strong 
and weak points of the pharmaceutical sector are taken into consideration in the article and further interventions to support a 
sustainable development are proposed by the author. 
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Introduction
The state of health constitutes a key factor for 
productivity and the development of the population both 
socially and professionally, but also for the welfare and 
psychological comfort at an individual level. States 
worldwide, irrespective of their economical power, try to 
insure a better health service taking into consideration the 
direct relationship between health and productivity, but 
also the overall cost.  
  In a different view, health services are an 
indispensable premise for insuring the state of health in 
the way defined by the World Health Organization – as a 
state of physical, psychical and social well-being. 
Until the mid-80s, the simple basic condition 
required for manufacturing medicines were not available 
in Syria. Syria relied entirely on importing the medicines, 
having only two laboratories - Tamiko and Dimas - that 
belonged to the governmental sector. These two 
companies used only 6% of the requirements to cover the 
local market. Therefore, with the help and encouragement 
of the government, the private sector started to invest in 
the pharmaceutical industry by establishing of new plants 
and laboratories under the supervision and control of the 
Ministry of Health that cooperated with international 
organizations and pharmaceutical laboratories in 
implementing an intensive program meant to update all 
the aspects of the Pharmaceutical industry through the 
development of legislative and regulatory systems. 
Laboratories and production lines have been designed 
according to the conditions set by the World Health 
Organizations and the Global Companies. The regulations 
of good manufacturing practice (GMP) which were not 
known in Syria before 1988 became commonly used. A 
series of ISO standards for quality management systems 
(ISO 900), manufacturing of pharmaceutical products, 
storage conditions and environment management (ISO 
1400) were implemented.  
Achievements 
The number of pharmaceutical factories in Syria 
has reached 63, producing 5700 types of products and 
offering jobs to about 17000 workers. 
Today, we can say that the pharmaceutical 
industry has become one of the most important pillars of 
economic and social development in Syria. The local 
drugs production covers almost 90% of the national needs 
of Syria. 
A plan meant to promote the production of 
generic drugs for cancer treatment, medicines related to 
blood diseases, vaccines, etc., and to cover 98 - 99% of 
the Syrian health sector needs is being implemented. 
According to this plan, the above-mentioned products will 
be manufactured locally within the next two years.  Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
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The basic elements that make the 
pharmaceutical industry contribute to the national 
GDP are: 
1.  Covering the local market and reducing the 
import of medicines, which reached a minimum of 700 
million dollars. 
2.  Production reached almost 600 million 
dollars; the local market consumes more than 400 million 
dollars and the rest is sent for export. 
3.  Employing over 17000 workers of different 
qualification levels, university graduates, technicians and 
labors, out of which 85% are women. 
4.  Using modern and high technologies and 
implementing the principle of the high quality. 
5.  Running the pharmaceutical sector and 
related industry. 
Due to the intensive ongoing training & 
rehabilitation programs, there are a large number of 
qualified workers with very high level of efficiency in the 
Pharmaceutical industry in Syria; over 25% of them are 
university graduates. 
Output of the Pharmaceutical Industries 
Following the coefficient of the Syrian medicine 
on the map of the pharmacological treatment, we have 
found that with a few exceptions, most of the products 
meet the international standard systems. The exceptions 
are because either the products are new or they are 
protected by Patent Paw, and patent owning companies 
do not usually grant Production License to other 
companies, especially in the developing countries. 
Nevertheless, and as a result of the success achieved by 
the laboratories in developing new and modern 
techniques/technologies, lots of the major international 
pharmaceutical companies started to grant the 
manufacturing concession to a number of 16 Syrian 
laboratories. Over 58 international companies are now 
giving licenses for almost 390 products/formulas to be 
produced in Syria - a total of 8.5% of the whole products 
that are manufactured locally. Interaction and better 
communication between Syrian and foreign laboratories 
will allow access to a better exchange of information that 
will lead to an increasing rate of industrialization. 
Advanced position despite the challenges 
Although Syria holds the second place in 
pharmaceutical production in the Arab world, exporting to 
more than 52 countries, there are still many challenges 
the pharmaceutical industry in Syria has to face: 
1.  Covering more than 90% of the 
pharmaceutical needs locally and nationally; 
2.  Availability of raw materials in the local 
market, achieving autonomy in the national industry; 
3.  Reviewing the medicines pricing base in 
accordance with the international specifications and within 
the moderate price range, elimination of foreign medicine, 
which are very expensive and helping producers to 
continue producing. 
4.  Lack of transparency and information 
about this type of business, the discrimination as far as 
the taxes and the absence of technical aspects to the 
certificate of origin are concerned. 
Advantages are viability, competitiveness, fast 
development, ability to cover the local market, capability 
to reduce the import of medicines that had raised to 700 
million dollars annually, capacity to produce drugs for 
more than 400 million dollars for the local market and 150 
million dollars for export annually, possibility to offer about 
17000 job opportunities.  
Disadvantages of this system might be the 
development and growth of the pharmaceutical industry is 
done more horizontally than vertically; lack of attention to 
the production of the raw materials, which are still 
imported from abroad; weak cooperation between Syrian 
pharmaceutical companies and weakness in the pricing 
mechanisms. 
 
Development initiatives and strategy through 
the following actions: 
•  Establishment of a national observation 
office to collect information about the pharmaceutical and 
internationall markets in close cooperation with the 
Ministry of Foreign Affairs and the diplomatic missions 
abroad. 
•  Establishment of a national center of 
excellence for recognition and equivalence of 
diplomas/studies in collaboration with the Ministries of 
Education and Health. 
•  Solving problems related to the product 
price in the country of origin, which is an obstacle in 
obtaining favorable export prices of the products. 
•  Encourage exporters through tax exemption 
to ensure competitive prices for products. 
•  Issuance of a set of rules /decisions such as 
licenses for the organization of pharmaceutical plants 
according to the requirements, re-evaluation of custom 
duties and services in the countryside. 
•  Preparing to compete based on the 
specifications and quality rather than quantity. 
•  The necessity to apply and follow the 
regulations of good manufacturing practice system in all 
pharmaceutical laboratories that will make the Syrian 
products competitive not only in the domestic market but 
also internationally. 
•  There should be incentives such as loans 
and industrial land and legislative development systems, 
pricing, and good investment in the pharmaceutical sector 
with reference to a simple price advantage, therefore 
external agreements must be signed in order to unify the  Journal of Medicine and Life Vol. 3, No. 3, July‐September 2010 
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export price of the Syrian medicines to help it get a 
prominent place in the world.  
•  Establishment of a national independent 
department in charge of Pharmaceutical industries, 
affiliated to the Ministry of Health and having full power to 
make decisions that aim to the improvement of product 
quality, development of Syrian pharmaceutical industry to 
such high standards that the domestic product could 
cover all the consumers’ needs and be comparable in 
quality with the best products produced by global 
competitors. 
All of the above-mentioned conditions will 
contribute to the development of the health system and 
will help in the achievement of positive results in all areas 
of medical health. Moreover, curative services will 
increase their capacity, bringing funds to the health sector 
that will increase the quality of health services for the 
benefit of both the doctor and the patient, as the 
pharmaceutical sector has a major importance in health 
and medical system/business.  
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